sisplatien, nivolumab
Nivolumab in kombinasie met cisplatin en gemcitabine word deur die USFDA goedgekeur vir onopskepbare of metastatiese urotheelkarsinoom
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
Pembrolizumab, USFDA
Enfortumab vedotin-ejfv met pembrolizumab is deur die USFDA goedgekeur vir plaaslik gevorderde of metastatiese urotheelkarsinoom
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
Bristol Myers Squibb, KONTROLEMAAT-274, nivolumab, Wonderlik, Urotheliale karsinoom
Nivolumab is deur die FDA goedgekeur vir gebruik as 'n hulpmiddel vir urotheelkarsinoom
August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence following rad..
Astellas Pharma VS, NCT03474107, Padcev, Proef EV-301
Die FDA het enfortumab vedotin-ejfv goedkeuring verleen vir die behandeling van plaaslik gevorderde of metastatiese urotheliale karsinoom
Augustus 2021: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), 'n kombinasie van teenliggaampies en mikrotubule-remmers wat deur Nectin-4 gerig is, is deur die Food and Drug Administration goedgekeur vir volwasse pasiënte met plaaslike advies.
Immunomedici Inc, mUC, platinumbevattende chemoterapie, geprogrammeerde doodsreseptor-1, sacituzumab govitecan, Trodelvy, TROFEE
Sacituzumab govitecan ontvang vinnige goedkeuring van die FDA vir gevorderde urotheelkanker
Augustus 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) het 'n versnelde goedkeuring van die Food and Drug Administration gekry vir pasiënte met plaaslik gevorderde of metastatiese urotheliale kanker (mUC) wat voorheen ontvang het.